Authors
Latest:
Immediate Impact Anticipated From Neoadjuvant PertuzumabThe new indication for pertuzumab (Perjeta) as part of a three-drug neoadjuvant regimen for patients with HER2-positive metastatic breast cancer marks the first time the FDA has authorized a therapy based on pathologic complete response.
Latest:
Dr. Gartrell on Tolerability of SM-88 in Prostate CancerBenjamin A. Gartrell, MD, assistant professor of urology, Albert Einstein College of Medicine, medical oncologist, Montefiore Medical Center, discusses the tolerability of SM-88 in the treatment of patients with prostate cancer.
Latest:
Commentary: It's Time to Repackage the Fight Against CigarettesTwenty million people in the United States have died from cigarette smoking since 1965.
Latest:
Dr. Youngblood on the Process of T-Cell Differentiation in Pediatric Solid TumorsBenjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.
Latest:
Future Research Directions in ALK+ and ROS1+ NSCLCGregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Latest:
Dr. Benjamin D. Smith on Mastectomy Versus Lumpectomy for Early Breast CancerBenjamin D. Smith, MD, associate professor and research director of breast radiation oncology, The University of Texas MD Anderson Cancer Center, Houston, discusses complications with mastectomy versus lumpectomy for early breast cancer.
Latest:
Dr. Heyman on the ALPINE Trial in CLLBenjamin Heyman, MD, discusses the phase 3 ALPINE trial in chronic lymphocytic leukemia.
Latest:
Research Findings Point to Clinical Importance of Clonal HematopoiesisAlthough clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.
Latest:
Dr. Lampson on Safety and Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab in CLLBenjamin L. Lampson, MD, PhD, medical oncologist at Dana-Farber Cancer Institute, discusses preliminary safety and efficacy results from a phase II study of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).
Latest:
Closing Thoughts on Evolving Antibody-Drug Conjugate LandscapeThe expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Latest:
Refining EGFR Classifications and Impact on Treatment for NSCLCExperts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.
Latest:
Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
Latest:
Future Directions in the Management of Renal Cell CarcinomaShared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.
Latest:
Key Takeaways: Advancements and Challenges in Kidney Cancer TreatmentLeading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.
Latest:
Dr. Anderson on the Unmet Need in Low- and Middle-Income Breast Cancer CareBenjamin O. Anderson, MD, a surgical oncologist at the Seattle Cancer Care Alliance, discusses the biggest unmet need for patients with breast cancer in low- and middle-income countries.
Latest:
Clinical Pearls and Future Perspectives in Advanced NSCLCThe expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.
Latest:
Uncommon EGFR Mutations in NSCLC: Real-World Selection and Use of Novel AgentsBenjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, reflect on their experience managing real-world patients with uncommon EGFR mutations in non–small cell lung cancer.
Latest:
Evolving Field of Molecular Testing in Non–Small Cell Lung CancerExpert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.
Latest:
Uncommon EGFR Mutations in NSCLC: Future Directions in CareClosing out their discussion on uncommon EGFR mutations in non–small cell lung cancer, Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, consider how the treatment paradigm will continue to evolve.
Latest:
Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint FleurOncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Focusing on Your Patient's NeedsAlthough the ever-expanding list of targeted drugs, and the seemingly relentless stack of evidence-based trials are daunting, the toughest yet most important lesson to me so far is to realize when doing everything is not warranted, necessary, desired, or feasible.
